There was a significant lower presence of mutations involving FLT3 (6 vs. 19%; p = 0.02), RAS (4 vs. 14%; p = 0.04), and NPM1 (8 vs. 20%; p = 0.03) genes in mutant-TP53 AML in comparison with WT-TP53 AML (41). This evidence concerns the gene NPM1 and acute myeloid leukemia.